Prevention of Respiratory Syncytial Virus–Related Hospitalization in Newborns

To the Editor A recent article compared the real-world effectiveness of the 2 available immunization strategies against respiratory syncytial virus (RSV): passive infant immunization with the long-acting monoclonal antibody nirsevimab vs maternal vaccination with the RSV prefusion F protein (RSVpreF) vaccine. Nirsevimab was associated with lower risk of RSV-related hospitalization, admission to the pediatric intensive care unit, need for ventilatory support, and oxygen treatment. Nonetheless, we...